Topics
4 signals
Washington State has reached a $96.5 million settlement with various generic drug companies over price-fixing allegations from 2009 to 2019. This settlement has significant implications for healthcare procurement professionals, who must navigate the consequences of increased scrutiny on pricing practices and potential regulatory changes.
The Centers for Medicare & Medicaid Services (CMS) has begun its GENEROUS Model aimed at aligning Medicaid drug prices with international standards. This initiative, involving all 50 states, is projected to save $64.3 billion over ten years and necessitates updates in contracting within the healthcare sector.
The Department of Veterans Affairs (VA) has achieved over **$10.44 billion** in pharmaceutical price reductions for FY 2026, significantly enhancing its purchasing power and enabling broader healthcare access for veterans. This success underscores evolving procurement strategies that may impact vendor negotiations and contract opportunities in the pharmaceutical sector.
The HHS and CDC hold over $1.24 billion in Pfizer contracts for COVID-19 vaccines that remain inactive. This uncertainty impacts procurement strategies and planning for contractors involved in vaccine distribution and development.